Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) EBIT (2016 - 2025)

Historic EBIT for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to -$22.9 million.

  • Tandem Diabetes Care's EBIT rose 1237.88% to -$22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$196.1 million, marking a year-over-year decrease of 4679.99%. This contributed to the annual value of -$99.1 million for FY2024, which is 5749.82% up from last year.
  • As of Q3 2025, Tandem Diabetes Care's EBIT stood at -$22.9 million, which was up 1237.88% from -$51.8 million recorded in Q2 2025.
  • Tandem Diabetes Care's EBIT's 5-year high stood at $12.7 million during Q4 2021, with a 5-year trough of -$127.8 million in Q1 2023.
  • For the 5-year period, Tandem Diabetes Care's EBIT averaged around -$31.5 million, with its median value being -$26.1 million (2024).
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 86511.4% in 2021, then crashed by 73333.55% in 2023.
  • Tandem Diabetes Care's EBIT (Quarter) stood at $12.7 million in 2021, then crashed by 239.56% to -$17.8 million in 2022, then crashed by 97.22% to -$35.1 million in 2023, then skyrocketed by 98.34% to -$581000.0 in 2024, then tumbled by 3835.11% to -$22.9 million in 2025.
  • Its last three reported values are -$22.9 million in Q3 2025, -$51.8 million for Q2 2025, and -$120.9 million during Q1 2025.